IN BRIEF: Sareum Gets GBP174,000 To Research Potential Virus Treatment

Thu, 03rd Dec 2020 15:45

Sareum Holdings PLC - Cambridge-based specialist drug development company focused on cancer and autoimmune diseases - Receives GBP174,000 grant from UK Research & Innovation to investigate TYK2/JAK1 kinase inhibitor as a treatment for severe Covid-19. "If this research and the ongoing preclinical development of SDC-1801 is successful, and subject to further funding, Sareum would aim to begin a clinical trial of SDC-1801 in severe-phase Covid-19 patients during 2021," Sareum says.

Current stock price: 1.42 pence

Year-to-date change: up sharply from 0.36p

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities...

4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent conc...